Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (688505.SS)
CNY 8.14
(-0.25%)
CNY 8.14
(-0.25%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 71.01 Million | 165.26 Million | 268.89 Million | 113 Million | 269.23 Million | 173.93 Million |
| Net Income | 108.62 Million | 137.27 Million | 212.38 Million | 164.25 Million | 220.65 Million | 143.07 Million |
| Depreciation & Amortization | 62.23 Million | 80.97 Million | 60.85 Million | 53.61 Million | 56.67 Million | 53.21 Million |
| Deferred income taxes | -14.96 Million | -6.67 Million | -22.68 Million | -4.79 Million | -16.65 Million | -36.53 Million |
| Stock-based compensation | -1.84 Million | 7.68 Million | 64.97 Million | - | - | - |
| Change in working capital | -122.99 Million | -60.28 Million | -48.63 Million | -103.8 Million | -17.24 Million | -19.31 Million |
| Other non-cash items | 253.68 Million | 6.3 Million | 2.01 Million | -1.06 Million | 9.15 Million | -3.03 Million |
| Investing Cash Flow | -45.37 Million | -96.74 Million | -355.67 Million | -46.53 Million | -21.14 Million | -48.63 Million |
| Investments in PPE | -98.96 Million | -87.3 Million | -120.11 Million | -42.41 Million | -40.38 Million | -37.78 Million |
| Acquisitions | 678.18 Thousand | 1.44 Million | -259.61 Million | -36 Million | 6.79 Million | -24 Million |
| Investment purchases | -3.9 Billion | -4.02 Billion | -3.48 Billion | -3.08 Billion | -1.66 Billion | -1.86 Billion |
| Sales/Maturities of investments | 3.96 Billion | 4.01 Billion | 3.24 Billion | 3.1 Billion | 1.66 Billion | 1.88 Billion |
| Other Investing Activities | 53.59 Million | -10.88 Million | 267.66 Million | 12.02 Million | 2.61 Million | 1.09 Million |
| Financing Cash Flow | -118.97 Million | 11.6 Million | -101.16 Million | 753.84 Million | -259.56 Million | -5.39 Million |
| Debt repayment | -100 Million | -101 Million | -7.5 Million | -200 Million | -150 Million | -140 Million |
| Dividends payments | -72.56 Million | -72.03 Million | -52.15 Million | -64.61 Million | -64.61 Million | -27.69 Million |
| Common Stock Repurchased | - | -8.69 Million | -40.82 Million | -945.13 Million | - | - |
| Common Stock Issuance | 66.86 Million | -92.3 Million | 48.32 Million | 996.19 Million | - | - |
| Other Financing Activities | -3.9 Million | 284.64 Million | -49.01 Million | 972.55 Million | -39.37 Million | 162.29 Million |
| Accounts receivables | -10.47 Million | -89.72 Million | -95.37 Million | -83.53 Million | -122.9 Million | -206.1 Million |
| Accounts payables | -74.05 Million | 48.71 Million | 72.56 Million | -2.54 Million | 134.11 Million | 211.96 Million |
| Inventory | -6.57 Million | -5.84 Million | 318.19 Thousand | -5.41 Million | -4.32 Million | 6.97 Million |
| Other working capital | -31.89 Million | -13.43 Million | -26.14 Million | -12.31 Million | -24.13 Million | -26.28 Million |
| Cash at beginning of period | 1.28 Billion | 1.2 Billion | 1.39 Billion | 576.79 Million | 588.22 Million | 468.14 Million |
| Cash at end of period | 1.19 Billion | 1.28 Billion | 1.2 Billion | 1.39 Billion | 576.79 Million | 588.22 Million |
| Capital Expenditure | -98.96 Million | -87.3 Million | -120.11 Million | -42.41 Million | -40.38 Million | -37.78 Million |
| Effect of forex changes on cash | -68.23 Thousand | 292.77 Thousand | -74.18 Thousand | -224.43 Thousand | 56.18 Thousand | 164 Thousand |
| Net cash flow / Change in cash | -93.4 Million | 80.42 Million | -188 Million | 820.09 Million | -11.42 Million | 120.07 Million |
| Free Cash Flow | -27.95 Million | 77.96 Million | 148.78 Million | 70.59 Million | 228.84 Million | 136.15 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 15.99 Million | 68.12 Million | 2.34 Million | 18.73 Million | 108.62 Million | 21.45 Million |
| Depreciation & Amortization | - | 17.1 Million | 17.1 Million | 14.81 Million | 62.23 Million | -28.48 Million |
| Deferred income taxes | - | - | - | -10.73 Million | -14.96 Million | -108.77 Million |
| Stock-based compensation | - | - | - | -1.84 Million | -1.84 Million | 1.84 Million |
| Change in working capital | - | -17.69 Million | - | -17.04 Million | -122.99 Million | 135.41 Million |
| Other non-cash items | -103.79 Million | -67.3 Million | 41.59 Million | 65.38 Million | 253.68 Million | 89.01 Million |
| Investing Cash Flow | -3.34 Million | 8.13 Million | -3.8 Million | -9.88 Million | -45.37 Million | -26.78 Million |
| Investments in PPE | -7.9 Million | 2.24 Million | -10.53 Million | -13.32 Million | -98.96 Million | -31.52 Million |
| Acquisitions | -1.63 Million | 1.92 Million | 428.18 Thousand | -732.13 Thousand | 678.18 Thousand | 3114.00 |
| Investment purchases | 2 Billion | -2 Billion | - | -3.9 Billion | -3.9 Billion | 2.08 Billion |
| Sales/Maturities of investments | -2.01 Billion | 2.01 Billion | - | 3.96 Billion | 3.96 Billion | -2.12 Billion |
| Other Investing Activities | 14.7 Million | 913 Million | 6.29 Million | -48.73 Million | 53.59 Million | 48.73 Million |
| Financing Cash Flow | -92.43 Million | -2.85 Million | -2.66 Million | -105.8 Million | -118.97 Million | -72.32 Million |
| Debt repayment | - | - | -2.66 Million | -100 Million | -100 Million | - |
| Dividends payments | - | - | - | -72.56 Million | -72.56 Million | -71.9 Million |
| Common Stock Repurchased | - | - | - | - | - | -1.00 |
| Common Stock Issuance | - | - | - | 66.86 Million | 66.86 Million | - |
| Other Financing Activities | -92.43 Million | 2.66 Million | -2.66 Million | 9.26 Million | -3.9 Million | -418.11 Thousand |
| Accounts receivables | - | -7.45 Million | - | -10.47 Million | -10.47 Million | 125.11 Million |
| Accounts payables | - | - | - | - | -74.05 Million | - |
| Inventory | - | -10.24 Million | - | -6.57 Million | -6.57 Million | 10.29 Million |
| Other working capital | - | - | - | - | -31.89 Million | - |
| Cash at beginning of period | 1.22 Billion | 1.23 Billion | 1.19 Billion | 1.24 Billion | 1.28 Billion | 1.23 Billion |
| Cash at end of period | 1.03 Billion | 1.22 Billion | 1.23 Billion | 1.19 Billion | 1.19 Billion | 1.24 Billion |
| Capital Expenditure | -7.9 Million | 2.24 Million | -10.53 Million | -13.32 Million | -98.96 Million | -31.52 Million |
| Effect of forex changes on cash | - | 94.91 Thousand | 36.71 Thousand | -175.32 Thousand | -68.23 Thousand | -22.88 Thousand |
| Net cash flow / Change in cash | -183.93 Million | -10.91 Million | 37.49 Million | -46.56 Million | -93.4 Million | 11.33 Million |
| Free Cash Flow | -95.7 Million | -14.04 Million | 33.4 Million | 55.97 Million | -27.95 Million | 78.93 Million |
HYPOF
688315
HLFN
0LID
PETKM
GLL